Pharma BD Deal Intelligence
Pfizer paid ~$195M for a PAH drug the FDA had already rejected twice, then watched it get pulled worldwide in 2010 over fatal liver toxicity — a near-total loss.
Full analysis, sources & comparables →The $2.35-per-share buyout — a 117% premium — saves the struggling biotech from NASDAQ delisting after Thelin received three approvable letters from FDA, the…
Pfizer announced cash tender offer at $2.35/share (~$195M equity value) to acquire Encysive, citing near-term EU revenue from Thelin and complementarity with…
Pfizer voluntarily withdrew sitaxentan worldwide on December 10, 2010 citing fatal liver damage; the drug had failed three FDA approvable cycles and never…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Pfizer acquired Encysive Pharmaceuticals via a cash tender offer at $2.35 per share (approximately $195 million equity value, a roughly 117-118% premium), gaining Thelin (sitaxentan), an oral pulmonary arterial hypertension drug already approved in the EU, Australia and Canada but still pending U.S. FDA approval after three approvable letters. Pfizer planned a required Phase III trial to pursue U.S. approval alongside its existing Revatio PAH franchise; Pfizer voluntarily withdrew sitaxentan worldwide in December 2010 after reports of fatal liver damage.
Pfizer paid ~$195M for a PAH drug the FDA had already rejected twice, then watched it get pulled worldwide in 2010 over fatal liver toxicity — a near-total loss.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Encysive Pharmaceuticals Inc. (this deal) | 2008 | $195M | 9 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2008 deals · Pfizer Inc. deals